A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer

Abstract
159 “poor risk” patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1,3,5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1–5, 15–19, and 29–33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P=0.0007), and less nausea and vomiting (P=0.03).

This publication has 0 references indexed in Scilit: